Asthma Definition Pathophysiology Pathogenesis 1 Asthma is a
![](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-1.jpg)
![Asthma: Definition, Pathophysiology & Pathogenesis (1) Ø Asthma is a chronic inflammatory disorder of Asthma: Definition, Pathophysiology & Pathogenesis (1) Ø Asthma is a chronic inflammatory disorder of](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-2.jpg)
![Asthma: Definition, Pathophysiology & Pathogenesis (2) Ø Gene-by-environment interactions are important to the expression Asthma: Definition, Pathophysiology & Pathogenesis (2) Ø Gene-by-environment interactions are important to the expression](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-3.jpg)
![Asthma: pathogenesis Asthma: pathogenesis](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-4.jpg)
![Pathogenetic Mechanism of Asthma Pathogenetic Mechanism of Asthma](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-5.jpg)
![](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-6.jpg)
![](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-7.jpg)
![](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-8.jpg)
![](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-9.jpg)
![](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-10.jpg)
![](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-11.jpg)
![](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-12.jpg)
![Diagnosis of Asthma Diagnosis of Asthma](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-13.jpg)
![](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-14.jpg)
![Symptoms and Signs of Asthma • The cardinal symptoms of asthma : the combination Symptoms and Signs of Asthma • The cardinal symptoms of asthma : the combination](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-15.jpg)
![Asthma: dyspnea Asthma: dyspnea](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-16.jpg)
![Physical Examination • Examination of the chest in patients with mild intermittent asthma: typically Physical Examination • Examination of the chest in patients with mild intermittent asthma: typically](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-17.jpg)
![Laboratory Diagnosis of Asthma (1) • Pulmonary Function Tests: establish the diagnosis of asthma, Laboratory Diagnosis of Asthma (1) • Pulmonary Function Tests: establish the diagnosis of asthma,](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-18.jpg)
![Typical Spirometric (FEV 1) Tracings Volume FEV 1 Normal Subject Asthmatic (After Bronchodilator) Asthmatic Typical Spirometric (FEV 1) Tracings Volume FEV 1 Normal Subject Asthmatic (After Bronchodilator) Asthmatic](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-19.jpg)
![FV curve Pre-&post-BD FV curve Pre-&post-BD](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-20.jpg)
![Bronchoprovocation: Methacholine challenge test Normal BHR (+) Bronchoprovocation: Methacholine challenge test Normal BHR (+)](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-21.jpg)
![Mini-Wright Peak Flow Meter Mini-Wright Peak Flow Meter](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-22.jpg)
![A Simple Index of PEF Variation Highest PEF (670) PEF (L/min) 800 700 600 A Simple Index of PEF Variation Highest PEF (670) PEF (L/min) 800 700 600](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-23.jpg)
![Laboratory Diagnosis of Asthma • Tests for Ig. E Antibodies/ serum total Ig. E Laboratory Diagnosis of Asthma • Tests for Ig. E Antibodies/ serum total Ig. E](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-24.jpg)
![Acute asthma: chest X-ray Acute asthma: chest X-ray](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-25.jpg)
![Acute asthma: chest X-ray Acute asthma: chest X-ray](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-26.jpg)
![Mucus Plug in Bronchial Asthma One of the response of the bronchiole in asthma Mucus Plug in Bronchial Asthma One of the response of the bronchiole in asthma](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-27.jpg)
![Curschmann's spiral in sputum from asthma patient • CURSCHMANN'S SPIRAL - Spiral shaped mucous Curschmann's spiral in sputum from asthma patient • CURSCHMANN'S SPIRAL - Spiral shaped mucous](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-28.jpg)
![CHARCOT LEYDEN CRYSTALS, MICRO - Eosinophilic needleshaped crystalline structures. Represents breakdown products of eosinophils. CHARCOT LEYDEN CRYSTALS, MICRO - Eosinophilic needleshaped crystalline structures. Represents breakdown products of eosinophils.](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-29.jpg)
![Differential Diagnosis of Asthma • • Chronic Obstructive Pulmonary Disease (COPD) Cardiac Asthma Pulmonary Differential Diagnosis of Asthma • • Chronic Obstructive Pulmonary Disease (COPD) Cardiac Asthma Pulmonary](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-30.jpg)
![Treatment of Asthma Treatment of Asthma](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-31.jpg)
![2007 - Guidelines For The Diagnosis & Management Of Asthma Expert Review Panel (EPR-3) 2007 - Guidelines For The Diagnosis & Management Of Asthma Expert Review Panel (EPR-3)](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-32.jpg)
![Key Points – Asthma Control (Goals of Therapy) Reducing impairment – Prevent chronic & Key Points – Asthma Control (Goals of Therapy) Reducing impairment – Prevent chronic &](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-33.jpg)
![Key Points – Asthma Control (Goals of Therapy) Reducing Risk – Prevent recurrent exacerbations Key Points – Asthma Control (Goals of Therapy) Reducing Risk – Prevent recurrent exacerbations](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-34.jpg)
![Asthma Control = Asthma Goals Ø Ø Definition of asthma control is the same Asthma Control = Asthma Goals Ø Ø Definition of asthma control is the same](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-35.jpg)
![Assessing Asthma Control In Youths 12 Years of Age & Adults Assessing Asthma Control In Youths 12 Years of Age & Adults](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-36.jpg)
![NOT Currently Taking Controllers NOT Currently Taking Controllers](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-37.jpg)
![Classifying Severity AFTER Control is Achieved – All Ages Classification of Asthma Severity Lowest Classifying Severity AFTER Control is Achieved – All Ages Classification of Asthma Severity Lowest](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-38.jpg)
![Key Points - Medications Ø Controller medications: – Corticosteroids – Long Acting Beta Agonists Key Points - Medications Ø Controller medications: – Corticosteroids – Long Acting Beta Agonists](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-39.jpg)
![Stepwise Approach for Managing Asthma in Youths >12 Years of Age & Adu Intermittent Stepwise Approach for Managing Asthma in Youths >12 Years of Age & Adu Intermittent](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-40.jpg)
![](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-41.jpg)
- Slides: 41
![](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-1.jpg)
![Asthma Definition Pathophysiology Pathogenesis 1 Ø Asthma is a chronic inflammatory disorder of Asthma: Definition, Pathophysiology & Pathogenesis (1) Ø Asthma is a chronic inflammatory disorder of](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-2.jpg)
Asthma: Definition, Pathophysiology & Pathogenesis (1) Ø Asthma is a chronic inflammatory disorder of the airways. Ø The immunohistopathologic features of asthma include inflammatory cell infiltration. Ø Airway inflammation contributes to airway hyper-responsiveness, airflow limitation, respiratory symptoms, and disease chronicity. Ø In some patients, persistent changes in airway structure occur, including sub-basement fibrosis, mucus hyper-secretion, injury to epithelial cells, smooth muscle hypertrophy, and angiogenesis. (remodeling)
![Asthma Definition Pathophysiology Pathogenesis 2 Ø Genebyenvironment interactions are important to the expression Asthma: Definition, Pathophysiology & Pathogenesis (2) Ø Gene-by-environment interactions are important to the expression](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-3.jpg)
Asthma: Definition, Pathophysiology & Pathogenesis (2) Ø Gene-by-environment interactions are important to the expression of asthma. Ø Atopy, the genetic predisposition for the development of an immunoglobulin E (Ig. E)-mediated response to common aeroallergens, is the strongest identifiable predisposing factor for developing asthma. Ø Viral respiratory infections are one of the most important causes of asthma exacerbation and may also contribute to
![Asthma pathogenesis Asthma: pathogenesis](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-4.jpg)
Asthma: pathogenesis
![Pathogenetic Mechanism of Asthma Pathogenetic Mechanism of Asthma](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-5.jpg)
Pathogenetic Mechanism of Asthma
![](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-6.jpg)
![](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-7.jpg)
![](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-8.jpg)
![](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-9.jpg)
![](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-10.jpg)
![](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-11.jpg)
![](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-12.jpg)
![Diagnosis of Asthma Diagnosis of Asthma](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-13.jpg)
Diagnosis of Asthma
![](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-14.jpg)
![Symptoms and Signs of Asthma The cardinal symptoms of asthma the combination Symptoms and Signs of Asthma • The cardinal symptoms of asthma : the combination](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-15.jpg)
Symptoms and Signs of Asthma • The cardinal symptoms of asthma : the combination of shortness of breath, wheezing; chest tightness; and cough. • Dyspnea : as an isolated symptom can be attributed to asthma in at least 15% of patients evaluated for this complaint. • asthma has a circadian rhythm – characteristic increase in symptoms (e. g. , cough, dyspnea, and wheezing) during sleep – frequency of nocturnal asthma : key indicator of asthma severity
![Asthma dyspnea Asthma: dyspnea](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-16.jpg)
Asthma: dyspnea
![Physical Examination Examination of the chest in patients with mild intermittent asthma typically Physical Examination • Examination of the chest in patients with mild intermittent asthma: typically](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-17.jpg)
Physical Examination • Examination of the chest in patients with mild intermittent asthma: typically normal when performed between exacerbations • In more severe disease and during attacks – tachypnea, tachycardia – exaggeration of normal inspiratory fall of systolic blood pressure (pulsus paradoxus) > 10 mm. Hg – hyperinflation of the chest with flattened diaphragmatic excursion, use of accessory muscles of respiration, – hyperresonance of percussion note, prolongation of expiration, – inspiratory and expiratory musical-sonorous rhonchi and wheezes heard on auscultation • Absence of wheezing on auscultation – does not always mean lack of airway obstruction – patients with very severe obstruction may have minimal airflow
![Laboratory Diagnosis of Asthma 1 Pulmonary Function Tests establish the diagnosis of asthma Laboratory Diagnosis of Asthma (1) • Pulmonary Function Tests: establish the diagnosis of asthma,](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-18.jpg)
Laboratory Diagnosis of Asthma (1) • Pulmonary Function Tests: establish the diagnosis of asthma, to quantify the severity of the disease, and to monitor the course of the disease and response to therapy. – Spirometry – Bronchoprovocation- Nonspecific Airway Hyperresponsiveness • Pulse oximetry and arterial blood gas (ABG) measurements. • Self-monitoring by serial measurements and recordings of PEFRs (peak expiratory flow rates) – performed by the patient using a peak flow meter – provide insights into perceptions of airways obstruction; course of disease, including severity, response to therapy, and prediction and detection of exacerbation; and the identification of environmental precipitants of asthma
![Typical Spirometric FEV 1 Tracings Volume FEV 1 Normal Subject Asthmatic After Bronchodilator Asthmatic Typical Spirometric (FEV 1) Tracings Volume FEV 1 Normal Subject Asthmatic (After Bronchodilator) Asthmatic](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-19.jpg)
Typical Spirometric (FEV 1) Tracings Volume FEV 1 Normal Subject Asthmatic (After Bronchodilator) Asthmatic (Before Bronchodilator) 1 2 3 Time (sec) Note: Each FEV 1 curve represents the highest of three repeat measurements 4 5
![FV curve PrepostBD FV curve Pre-&post-BD](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-20.jpg)
FV curve Pre-&post-BD
![Bronchoprovocation Methacholine challenge test Normal BHR Bronchoprovocation: Methacholine challenge test Normal BHR (+)](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-21.jpg)
Bronchoprovocation: Methacholine challenge test Normal BHR (+)
![MiniWright Peak Flow Meter Mini-Wright Peak Flow Meter](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-22.jpg)
Mini-Wright Peak Flow Meter
![A Simple Index of PEF Variation Highest PEF 670 PEF Lmin 800 700 600 A Simple Index of PEF Variation Highest PEF (670) PEF (L/min) 800 700 600](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-23.jpg)
A Simple Index of PEF Variation Highest PEF (670) PEF (L/min) 800 700 600 500 Lowest PEF (600) Morning PEF Evening PEF 400 300 0 7 Days 14 PEFR variability: (Highest-Lowest PEFR)/ (Higest + Lowest) x ½ e. g. (670 -600) / (670+600) x ½ = 11%
![Laboratory Diagnosis of Asthma Tests for Ig E Antibodies serum total Ig E Laboratory Diagnosis of Asthma • Tests for Ig. E Antibodies/ serum total Ig. E](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-24.jpg)
Laboratory Diagnosis of Asthma • Tests for Ig. E Antibodies/ serum total Ig. E concentration • Peripheral blood eosinophil count • Microscopic examination of induced sputum or "wet preps" from patients with asthma – bronchial epithelial cells in clusters (Creola bodies) – eosinophils, Charcot-Leyden crystals – Curschmann's spirals of mucinous material of varying sizes from small airways • Chest radiographs – increased residual air manifested by overexpansion of the lungs with an increase of anteroposterior (AP) dimension, increase in retrosternal lucency, flattening of the diaphragm • Chest CT/High-resolution computed tomography (HRCT) : more sensitive for detecting subtle airways changes, such as early bronchiectasis, pulmonary fibrosis, and emphysema
![Acute asthma chest Xray Acute asthma: chest X-ray](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-25.jpg)
Acute asthma: chest X-ray
![Acute asthma chest Xray Acute asthma: chest X-ray](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-26.jpg)
Acute asthma: chest X-ray
![Mucus Plug in Bronchial Asthma One of the response of the bronchiole in asthma Mucus Plug in Bronchial Asthma One of the response of the bronchiole in asthma](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-27.jpg)
Mucus Plug in Bronchial Asthma One of the response of the bronchiole in asthma is the metaplastic proliferation of goblet or mucus-producing cells. Often, this results in the over-production of mucus, which plugs otherwise severely broncho-constricted bronchioles. One sometimes sees eosinophils within the mucus, occasionally with crystallized eosinophilic granules (Charcot-Leyden crystals).
![Curschmanns spiral in sputum from asthma patient CURSCHMANNS SPIRAL Spiral shaped mucous Curschmann's spiral in sputum from asthma patient • CURSCHMANN'S SPIRAL - Spiral shaped mucous](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-28.jpg)
Curschmann's spiral in sputum from asthma patient • CURSCHMANN'S SPIRAL - Spiral shaped mucous plug. Seen in asthma patients and patients with COPD.
![CHARCOT LEYDEN CRYSTALS MICRO Eosinophilic needleshaped crystalline structures Represents breakdown products of eosinophils CHARCOT LEYDEN CRYSTALS, MICRO - Eosinophilic needleshaped crystalline structures. Represents breakdown products of eosinophils.](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-29.jpg)
CHARCOT LEYDEN CRYSTALS, MICRO - Eosinophilic needleshaped crystalline structures. Represents breakdown products of eosinophils. Seen in asthma and eosinophilic pneumonia.
![Differential Diagnosis of Asthma Chronic Obstructive Pulmonary Disease COPD Cardiac Asthma Pulmonary Differential Diagnosis of Asthma • • Chronic Obstructive Pulmonary Disease (COPD) Cardiac Asthma Pulmonary](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-30.jpg)
Differential Diagnosis of Asthma • • Chronic Obstructive Pulmonary Disease (COPD) Cardiac Asthma Pulmonary Embolism Eosinophilic Lung Disease Carcinoid Tumor, carcinoid syndrome Mastocytosis In children – Viral bronchiolitis – Anatomic anomalies: vascular ring, T-E fistula, Rt. side aortic arch – Laryngomalacia – Gastroesophageal reflux disease (GERD) – Pneumonia – Pulmonary edema – Foreign body aspiration – Vocal cord dysfunction (VCD)
![Treatment of Asthma Treatment of Asthma](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-31.jpg)
Treatment of Asthma
![2007 Guidelines For The Diagnosis Management Of Asthma Expert Review Panel EPR3 2007 - Guidelines For The Diagnosis & Management Of Asthma Expert Review Panel (EPR-3)](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-32.jpg)
2007 - Guidelines For The Diagnosis & Management Of Asthma Expert Review Panel (EPR-3)
![Key Points Asthma Control Goals of Therapy Reducing impairment Prevent chronic Key Points – Asthma Control (Goals of Therapy) Reducing impairment – Prevent chronic &](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-33.jpg)
Key Points – Asthma Control (Goals of Therapy) Reducing impairment – Prevent chronic & troublesome symptoms. – Prevent frequent use (< 2 days /wk) of inhaled SABA for symptoms. – Maintain (near) “normal” pulmonary function. – Maintain normal activity levels (including exercise & other physical activity & attendance at work or school). – Meet patients’ and families’ expectations of and satisfaction with asthma care. EPR- 3, p. 50
![Key Points Asthma Control Goals of Therapy Reducing Risk Prevent recurrent exacerbations Key Points – Asthma Control (Goals of Therapy) Reducing Risk – Prevent recurrent exacerbations](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-34.jpg)
Key Points – Asthma Control (Goals of Therapy) Reducing Risk – Prevent recurrent exacerbations of asthma and minimize the need for ER visits and hospitalizations. – Prevent progressive loss of lung function - for children, prevent reduced lung growth. Ø Ø Ø – Provide optimal pharmacotherapy with minimal or no adverse effects. Periodic assessments at 1 -6 month intervals. Patient self-assessment (w/clinician). Spirometry testing. NAEPP 2007 guidelines, sec. 3, p. 53
![Asthma Control Asthma Goals Ø Ø Definition of asthma control is the same Asthma Control = Asthma Goals Ø Ø Definition of asthma control is the same](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-35.jpg)
Asthma Control = Asthma Goals Ø Ø Definition of asthma control is the same as asthma goals reducing impairment and risk. Monitoring quality of life, any: – work or school missed because of asthma? – reduction in usual activities? – disturbances in sleep due to asthma? – Change in caregivers activities due to a child's asthma?
![Assessing Asthma Control In Youths 12 Years of Age Adults Assessing Asthma Control In Youths 12 Years of Age & Adults](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-36.jpg)
Assessing Asthma Control In Youths 12 Years of Age & Adults
![NOT Currently Taking Controllers NOT Currently Taking Controllers](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-37.jpg)
NOT Currently Taking Controllers
![Classifying Severity AFTER Control is Achieved All Ages Classification of Asthma Severity Lowest Classifying Severity AFTER Control is Achieved – All Ages Classification of Asthma Severity Lowest](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-38.jpg)
Classifying Severity AFTER Control is Achieved – All Ages Classification of Asthma Severity Lowest level of treatment Intermittent required to maintain control Step 1 Persistent Mild Moderate Severe Step 2 Step 3 or 4 Step 5 or 6 (already on controller)
![Key Points Medications Ø Controller medications Corticosteroids Long Acting Beta Agonists Key Points - Medications Ø Controller medications: – Corticosteroids – Long Acting Beta Agonists](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-39.jpg)
Key Points - Medications Ø Controller medications: – Corticosteroids – Long Acting Beta Agonists (LABA’s) – Leukotriene modifiers (LTRA) – Cromolyn & Nedocromil Ø Methylxanthines: (Sustained-release theophylline) Ø Quick- relief medications – Short acting bronchodilators (SABA’s) – Systemic corticosteroids – Anticholinergics
![Stepwise Approach for Managing Asthma in Youths 12 Years of Age Adu Intermittent Stepwise Approach for Managing Asthma in Youths >12 Years of Age & Adu Intermittent](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-40.jpg)
Stepwise Approach for Managing Asthma in Youths >12 Years of Age & Adu Intermittent Asthma Persistent Asthma: Daily Medication Consult asthma specialist if step 4 care or higher is required. Consider consultation at step 3 Step 5 Step 4 Step 3 Preferred: Step 1 Low dose ICS Low-dose ICS + LABA OR – Medium dose ICS Preferred: SABA PRN Alternative: Cromolyn, LTRA, Nedocromil or Theophylline Alternative: Low -dose ICS + either LTRA, Theophylline, or Zileuton Step 2 Preferred: Preferred High Dose ICS + Preferred: Medium Dose ICS + LABA Alternative: Mediumdose ICS + either LTRA, Theophylline , or Zileuton LABA AND Consider Omalizumab for patients who have allergies Step 6 Step up if needed Preferred (first check adherence, environment al control & comorbid conditions) High dose ICS + LABA + oral corticosteroid AND Consider Omalizumab for patients who have allergies Assess control Step down if possible (and asthma is well controlled at least 3 months) Each Step: Patient Education and Environmental Control and management of comorbidities Steps 2 – 4: Consider subcutaneous allergen immunotherapy for patients who have allergic asthma • Quick-relief medication for ALL patients -SABA as needed for symptoms: up to 3 tx @ 20 minute intervals prn. Short course of o systemic corticosteroids may be needed. • Use of SABA >2 days a week for symptom relief (not prevention of EIB) generally indicates inadequate control & the need to step up treatment.
![](https://slidetodoc.com/presentation_image/3f297f447c70ca756d7e3df9e233f9cd/image-41.jpg)
Asthma pathophysiology
Asthma pathophysiology
Co2 narcosis
Asthma pathophysiology
Pathophysiology definition
Pathogenesis of pleomorphic adenoma
Uremia pathogenesis
Chronic calculous cholecystitis
Cholecystitis pathogenesis
Bacterial pathogenesis
Cholecystitis pathophysiology
Bacterial pathogenesis
Tetanus
Jaundice pathogenesis
Pathogenesis dengue fever
Rabies pathogenesis
Pathogenesis steps
Pathogenesis game
Pathogenesis of copd
Primary biliary cholangitis skin
Histoplasma capsulatum pathogenesis
Pathogenesis of chronic pyelonephritis
Pathophysiology of anemia diagram
Mechanism of ischemic stroke
Pathogenesis of tuberculosis
Panchajani
Dumping syndrome pathophysiology
Pathophysiology of epistaxis
Pathophysiology of tonsillitis
Hepatic encephalopathy pathophysiology
Thyroglossal cyst pathophysiology
Thyroid
Neonatal sepsis pathophysiology diagram
Pathophysiology signs and symptoms
Digestion
Thyroid storm pathophysiology
Pathophysiology of sodium and water retention
Taxis hernia
Multinodular goiter pathophysiology
Colloid defintion
Pathophysiology of hirschsprung disease
Hellp syndrome pathophysiology